CRSP CRISPR Therapeutics AG - Common Shares
$52,78
Preço · Ago 18, 2026
Fundamentais a partir de Ago 3, 2026
Intervalo 52 Semanas
$44–$78
25% of range
Classificação do Analista
HOLD
29 analysts
Preço-Alvo
$88
+66% upside
P/E (TTM)
-8.2
ROE
-32.0%
Margem de Lucro Líquido
-16569.8%
Sobre CRISPR Therapeutics AG - Common Shares Visão geral da empresa da Wikipedia
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
Ler mais
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
CRSP Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$52.77
Capitalização de Mercado
$5.06B
P/E (TTM)
-8.2
EPS (TTM)
$-6.47
Receita (TTM)
$4M
Rendimento div.
—
ROE
-32.0%
Dívida/Capital
—
Intervalo 52 Semanas
$44 – $78
CRSP Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$4M
2016-12-31
→
2025-12-31
EPS
$-6.47
2017-12-31
→
2025-12-31
Fluxo de caixa livre
$-346M
2016-12-31
→
2025-12-31
Margens
-16569.8%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
CRSP
Mediana de Pares
P/E (TTM)
-8.2
—
P/S (TTM)
1441.8
56.3
P/B
2.6
3.0
Price / FCF (Preço / FCF)
-14.6
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
CRSP
Mediana de Pares
Operating Margin (Margem Operacional)
-18933.7%
—
Net Profit Margin (Margem de Lucro Líquido)
-16569.8%
-1643.9%
ROA
-25.8%
-40.2%
ROE
-32.0%
-75.3%
ROIC
-34.8%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
CRSP
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
13.3
6.7
Quick Ratio (Índice de Liquidez Seca)
13.2
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
CRSP
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
-90.6%
—
Revenue CAGR 3Y (CAGR Receita 3A)
43.1%
—
Revenue CAGR 5Y (CAGR Receita 5A)
37.3%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
CRSP
Mediana de Pares
CRSP Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
29 analistas
- Compra forte 6 20,7%
- Compra 11 37,9%
- Manter 12 41,4%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
18 analistas · 2026-08-15
Mediana
$80.00
Agora
$52.77
Mín
$44.00
Máx
$291.00
Alvo mediano
$80.00
+51,6%
Alvo médio
$87.56
+65,9%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.01%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $-0.94 | $-1.22 | 0.28% |
| 31 de Março de 2026 | $-1.28 | $-1.25 | -0.03% |
| 31 de Dezembro de 2025 | $-1.37 | $-1.18 | -0.19% |
| 30 de Setembro de 2025 | $-1.17 | $-1.29 | 0.12% |
| 30 de Junho de 2025 | $-1.29 | $-1.45 | 0.16% |
| 31 de Março de 2025 | $-1.58 | $-1.28 | -0.30% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| CRSP | $5.03B | -8.1 | -90.6% | -16569.8% | -32.0% | — |
| MLTX | — | -3.7 | — | — | -60.5% | — |
| ACIU | — | — | — | — | — | — |
| ADCT | $444M | -3.2 | 14.8% | -175.3% | 74.1% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 15
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
Balanço Patrimonial 25
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
Fluxo de Caixa 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
Liquidez e Solvência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
Eficiência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
Taxas de Crescimento 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
Demonstração de Resultados 14
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
Balanço Patrimonial 25
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
Fluxo de Caixa 11
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
Liquidez e Solvência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
Eficiência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
Avaliação (TTM) 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $3M | $3M | $2M | · | $2M | $71M | $171M | · | $170M | $170M | $101M | · | $2M | |
| Net Income TTM | $-529M | $-574M | · | $-537M | $-557M | $-465M | · | $-441M | $-433M | $-360M | · | $-418M | $-491M | $-593M | · | $-667M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -9.4 | -7.4 | · | -10.5 | -7.5 | -6.2 | · | -8.8 | -10.2 | -15.2 | · | -8.6 | -8.9 | -5.9 | · | -7.6 | |
| P/S | 392.8 | 1117.2 | · | 1873.1 | 1494.7 | 1181.2 | · | 2470.2 | 64.7 | 33.9 | · | 21.2 | 26.2 | 35.2 | · | 2536.5 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| P / FCF | · | -41.9 | · | · | · | -54.3 | · | · | · | 53.0 | · | · | · | 621.4 | · | · | |
| Earnings Yield | -10.6% | -13.5% | · | -9.5% | -13.3% | -16.2% | · | -11.4% | -9.8% | -6.6% | · | -11.7% | -11.2% | -16.9% | · | -13.2% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $4M | $37M | $371M | $1M | $915M |
| Margem Operacional % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| Lucro líquido | $-582M | $-366M | $-154M | $-650M | $378M |
| EPS Diluído | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| Índice de Liquidez Seca | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-346M | $-145M | $-270M | $-533M | $457M |
Últimas notícias Notícias recentes mencionando esta empresa
- Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
- 2 Beaten-Down Stocks With Massive Upside Potential
- CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
- A Ação da CRISPR Therapeutics Está Absurdamente Barata -- Veja Por Que Analistas Veem Potencial de Alta de 437%
- Liderança de Crescimento de Mega-Cap ou Potencial de Crescimento de Pequena-Cap? VUG vs. VBK
- 1 Analista de Wall Street Acredita que CRISPR Therapeutics Poderia Mais Que Dobrar. Você Deveria Comprar as Ações a Qualquer Custo?
- Fluxo de ETF Notável Detectado - ARKK, CRSP, TEM, HOOD
- Esta Biotecnologia Tem um Pipeline Que Poderia Redefinir Toda a Sua Área Terapêutica
- Cathie Wood Vai à Caça de Barganhas: 2 Ações Que Ela Acabou de Comprar
- Esta Ação de Biotecnologia é Sua Melhor Chance de Construir uma Posição que Gera Milionários?
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 573 declarantes · $3.3B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 89 (0 vs trimestre anterior) | 47 (-13 vs trimestre anterior) | 148 (-24 vs trimestre anterior) | 145 (+21 vs trimestre anterior) | +5.4M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| ARK Investment Management LLC | $515.999.631 | 9.460.939 | 15,58% | Ações |
| Orbis Allan Gray Ltd | $296.334.582 | 5.433.344 | 8,95% | Ações |
| Capital World Investors | $259.039.094 | 4.749.525 | 7,82% | Ações |
| STATE STREET CORP | $235.703.664 | 4.321.666 | 7,12% | Ações |
| GSK plc | $175.652.997 | 3.220.627 | 5,30% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $117.453.717 | 2.153.015 | 3,55% | Ações |
| SR One Capital Management, LP | $111.194.134 | 2.038.763 | 3,36% | Ações |
| TWO SIGMA INVESTMENTS, LP | $108.459.389 | 1.988.621 | 3,27% | Ações |
| Sumitomo Mitsui Trust Group, Inc. | $93.848.832 | 1.720.734 | 2,83% | Ações |
| Amova Asset Management Americas, Inc. | $93.762.487 | 1.720.097 | 2,83% | Ações |
| EcoR1 Capital, LLC | $75.771.113 | 1.389.276 | 2,29% | Ações |
| Capital International Investors | $69.178.918 | 1.268.407 | 2,09% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $64.457.935 | 1.181.847 | 1,95% | Ações |
| NEA Management Company, LLC | $57.734.408 | 1.058.570 | 1,74% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57.694.430 | 1.057.837 | 1,74% | Ações |
| FMR LLC | $53.577.751 | 982.357 | 1,62% | Ações |
| D. E. Shaw & Co., Inc. | $48.748.506 | 893.812 | 1,47% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35.380.807 | 648.713 | 1,07% | Ações |
| UBS Group AG | $32.419.612 | 594.419 | 0,98% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $31.089.982 | 570.040 | 0,94% | Ações |
| VANGUARD GROUP INC | $27.714.225 | 528.494 | 0,84% | Ações |
| CITADEL ADVISORS LLC | $25.404.514 | 465.796 | 0,77% | Ações |
| BANK OF AMERICA CORP /DE/ | $23.509.740 | 431.055 | 0,71% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23.298.288 | 427.178 | 0,70% | Ações |
| MILLENNIUM MANAGEMENT LLC | $20.836.025 | 382.032 | 0,63% | Ações |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20.833.789 | 381.991 | 0,63% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18.456.336 | 338.400 | 0,56% | Opção de venda |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17.763.678 | 325.700 | 0,54% | Opção de compra |
| Logos Global Management LP | $16.362.000 | 300.000 | 0,49% | Ações |
| CITADEL ADVISORS LLC | $15.822.054 | 290.100 | 0,48% | Opção de venda |
| Squarepoint Ops LLC | $15.641.472 | 286.789 | 0,47% | Ações |
| NORGES BANK | $14.767.032 | 270.756 | 0,45% | Ações |
| CITADEL ADVISORS LLC | $13.973.148 | 256.200 | 0,42% | Opção de compra |
| GOLDMAN SACHS GROUP INC | $12.748.193 | 233.740 | 0,38% | Ações |
| JANE STREET GROUP, LLC | $12.566.016 | 230.400 | 0,38% | Opção de compra |
| PEAK6 LLC | $11.633.382 | 213.300 | 0,35% | Opção de venda |
| Swiss National Bank | $9.228.168 | 169.200 | 0,28% | Ações |
| Susquehanna Portfolio Strategies, LLC | $8.945.978 | 164.026 | 0,27% | Ações |
| TWO SIGMA ADVISERS, LP | $8.516.256 | 162.400 | 0,26% | Ações |
| LPL Financial LLC | $8.376.280 | 153.581 | 0,25% | Ações |
| Bank of New York Mellon Corp | $8.337.366 | 152.867 | 0,25% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $8.301.261 | 152.205 | 0,25% | Ações |
| Versant Venture Management, LLC | $8.117.243 | 148.831 | 0,25% | Ações |
| Pictet Asset Management Holding SA | $7.989.776 | 142.213 | 0,24% | Ações |
| Life Cycle Investment Partners Ltd | $7.836.962 | 143.692 | 0,24% | Ações |
| TD Asset Management Inc | $7.777.513 | 142.602 | 0,23% | Ações |
| AMERICAN CENTURY COMPANIES INC | $7.606.257 | 139.462 | 0,23% | Ações |
| RAYMOND JAMES FINANCIAL INC | $7.230.750 | 132.577 | 0,22% | Ações |
| RHUMBLINE ADVISERS | $6.627.197 | 121.511 | 0,20% | Ações |
| SFE Investment Counsel | $6.229.434 | 16.700 | 0,19% | Opção de venda |
| Private Advisor Group, LLC | $6.060.980 | 111.129 | 0,18% | Ações |
| EverSource Wealth Advisors, LLC | $6.032.669 | 110.610 | 0,18% | Ações |
| CONGRESS ASSET MANAGEMENT CO | $5.969.567 | 109.453 | 0,18% | Ações |
| BlackRock, Inc. | $5.937.061 | 108.857 | 0,18% | Ações |
| D. E. Shaw & Co., Inc. | $5.901.228 | 108.200 | 0,18% | Opção de compra |
| Campbell & CO Investment Adviser LLC | $5.864.632 | 107.529 | 0,18% | Ações |
| JANE STREET GROUP, LLC | $5.852.142 | 107.300 | 0,18% | Opção de venda |
| California Public Employees Retirement System | $5.599.567 | 102.669 | 0,17% | Ações |
| CAPITAL INTERNATIONAL SARL | $5.521.521 | 101.238 | 0,17% | Ações |
| Affinity Asset Advisors, LLC | $5.454.000 | 100.000 | 0,16% | Ações |
| ALLIANCEBERNSTEIN L.P. | $5.439.011 | 114.337 | 0,16% | Ações |
| CLOUGH CAPITAL PARTNERS L P | $5.363.300 | 98.337 | 0,16% | Ações |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $5.172.465 | 94.838 | 0,16% | Ações |
| Slow Capital, Inc. | $5.066.439 | 92.894 | 0,15% | Ações |
| CAPITAL FUND MANAGEMENT S.A. | $4.867.258 | 89.242 | 0,15% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $4.815.606 | 101.232 | 0,15% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $4.720.437 | 86.550 | 0,14% | Ações |
| GROUP ONE TRADING LLC | $4.638.082 | 85.040 | 0,14% | Ações |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | $4.575.742 | 83.897 | 0,14% | Ações |
| STATE OF MICHIGAN RETIREMENT SYSTEM | $4.502.113 | 82.547 | 0,14% | Ações |
| Concurrent Investment Advisors, LLC | $4.497.728 | 82.467 | 0,14% | Ações |
| WELLS FARGO & COMPANY/MN | $4.309.151 | 79.009 | 0,13% | Ações |
| Fisher Asset Management, LLC | $4.251.957 | 77.960 | 0,13% | Ações |
| Trexquant Investment LP | $4.225.268 | 77.471 | 0,13% | Ações |
| COMMONWEALTH EQUITY SERVICES, LLC | $4.194.122 | 76.900 | 0,13% | Ações |
| JONES FINANCIAL COMPANIES LLLP | $4.055.652 | 73.847 | 0,12% | Ações |
| Man Group plc | $3.992.001 | 73.194 | 0,12% | Ações |
| PEAK6 LLC | $3.834.162 | 70.300 | 0,12% | Opção de compra |
| ENVESTNET ASSET MANAGEMENT INC | $3.822.196 | 70.081 | 0,12% | Ações |
| ALGERT GLOBAL LLC | $3.593.095 | 65.880 | 0,11% | Ações |
| Walleye Trading LLC | $3.528.738 | 64.700 | 0,11% | Opção de venda |
| MILLENNIUM MANAGEMENT LLC | $3.146.958 | 57.700 | 0,10% | Opção de compra |
| CAPITAL INTERNATIONAL LTD /CA/ | $3.057.840 | 56.066 | 0,09% | Ações |
| NOMURA HOLDINGS INC | $3.055.713 | 56.027 | 0,09% | Ações |
| Rafferty Asset Management, LLC | $3.045.132 | 55.833 | 0,09% | Ações |
| Green Alpha Advisors, LLC | $3.043.550 | 55.804 | 0,09% | Ações |
| Walleye Trading LLC | $3.005.154 | 55.100 | 0,09% | Opção de compra |
| Caption Management, LLC | $2.999.700 | 55.000 | 0,09% | Opção de compra |
| MetLife Investment Management, LLC | $2.958.413 | 54.243 | 0,09% | Ações |
| BENJAMIN EDWARDS INC | $2.956.845 | 54.216 | 0,09% | Ações |
| Quantinno Capital Management LP | $2.869.349 | 52.610 | 0,09% | Ações |
| Cetera Investment Advisers | $2.856.133 | 52.368 | 0,09% | Ações |
| STATE OF WISCONSIN INVESTMENT BOARD | $2.788.521 | 51.128 | 0,08% | Ações |
| CITIGROUP INC | $2.781.540 | 51.000 | 0,08% | Opção de compra |
| CITIGROUP INC | $2.781.540 | 51.000 | 0,08% | Opção de venda |
| WOLVERINE ASSET MANAGEMENT LLC | $2.727.000 | 50.000 | 0,08% | Opção de venda |
| OSAIC HOLDINGS, INC. | $2.693.150 | 49.381 | 0,08% | Ações |
| Privium Fund Management B.V. | $2.452.882 | 44.974 | 0,07% | Ações |
| CANADA PENSION PLAN INVESTMENT BOARD | $2.394.306 | 43.900 | 0,07% | Ações |
| TUDOR INVESTMENT CORP ET AL | $2.318.604 | 42.512 | 0,07% | Ações |
Executivos da empresa 32 insiders · 12 diretores · 16 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 20 de Março de 2026 M | 255.501 | 0 | 9 | $-10.756.932 |
| Brendan Smith | Chief Financial Officer | 18 de Fevereiro de 2023 M | 5.072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | 11 de Março de 2021 M | 1.891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | 20 de Março de 2025 M | 10.544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | 16 de Agosto de 2022 A | 26.797 | 0 | 0 | $0 |
| Naimish Patel | Chief Medical Officer | 29 de Maio de 2026 A | 19.357 | 1 | 2 | $-312.892 |
| James R. Kasinger | General Counsel and Secretary | 29 de Maio de 2026 A | 94.308 | 0 | 5 | $-645.902 |
| Phuong Khanh Morrow | Chief Medical Officer | 13 de Outubro de 2023 A | 4.411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | 3 de Dezembro de 2021 M | 52.364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | 16 de Janeiro de 2018 M | 25.204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | 15 de Junho de 2017 A | — | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | 24 de Outubro de 2016 C | 505.617 | 0 | 0 | $0 |
| Christian Rommel | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| Harold Edward Fleming | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| Douglas A Treco | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| Briggs Morrison | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| Katherine A High | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| Ali Behbahani | Conselheiro | 5 de Junho de 2026 A | 14 | 0 | 0 | $0 |
| John Greene | Conselheiro | 5 de Junho de 2026 A | 7.000 | 0 | 0 | $0 |
| Simeon George | Conselheiro | 5 de Junho de 2026 A | 1.730.179 | 0 | 0 | $0 |
| Maria Fardis | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| Sandesh Mahatme | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| Bradley J Bolzon PhD | Conselheiro | 9 de Junho de 2022 A | 148.831 | 0 | 0 | $0 |
| Pablo J Cagnoni | Conselheiro | 19 de Novembro de 2019 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | Conselheiro | 18 de Dezembro de 2018 S | 1.171.268 | 0 | 0 | $0 |
| Thomas Woiwode | Conselheiro | 15 de Junho de 2018 A | 640.014 | 0 | 0 | $0 |
| Anthony N Coles | Conselheiro | 31 de Maio de 2017 A | 70.000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | Detentor de 10% | 4 de Dezembro de 2017 S | 3.722.534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | Detentor de 10% | 24 de Outubro de 2016 C | 744.380 | 0 | 0 | $0 |
| GSK plc | Detentor de 10% | 24 de Outubro de 2016 C | 3.220.627 | 0 | 0 | $0 |
| Raju Prasad | — | 7 de Agosto de 2026 G | 14.815 | 0 | 10 | $-5.100.841 |
| Rodger Novak | — | 30 de Junho de 2021 S | 573.007 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 6 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 declarações | 16 de Fevereiro de 2021 | — | Declaração inicial | — | SEC |
| GlaxoSmithKline plc ×5 declarações | 10 de Julho de 2020 | — | Declaração inicial | — | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 declarações | 4 de Fevereiro de 2020 | — | Declaração inicial | — | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 declarações | 7 de Junho de 2019 | — | Declaração inicial | — | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 declarações | 8 de Fevereiro de 2018 | — | Declaração inicial | — | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 declarações | 16 de Janeiro de 2018 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 32 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| GNOM · Global X Funds | 3,85% | 38.191 NS | 31 de Maio de 2026 | N-PORT |
| IDNA · iShares Trust | 1,63% | 62.247 SH | 8 de Agosto de 2026 | Diário |
| LABU · Direxion Shares ETF Trust | 0,98% | 97.235 NS | 30 de Abril de 2026 | N-PORT |
| IBB · iShares Trust | 0,36% | 658.537 SH | 8 de Agosto de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,35% | 5.248 SH | 8 de Agosto de 2026 | Diário |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,28% | 70.696 SH | 8 de Agosto de 2026 | Diário |
| IWN · iShares Trust | 0,27% | 752.223 SH | 8 de Agosto de 2026 | Diário |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,21% | 104.016 NS | 31 de Maio de 2026 | N-PORT |
| ISCV · iShares Trust | 0,15% | 20.568 SH | 8 de Agosto de 2026 | Diário |
| IWM · iShares Trust | 0,15% | 2.353.025 SH | 8 de Agosto de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,15% | 536.446 SH | 8 de Agosto de 2026 | Diário |
| RSSL · Global X Funds | 0,15% | 39.589 NS | 30 de Abril de 2026 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,10% | 6.636 SH | 8 de Agosto de 2026 | Diário |
| ISCB · iShares Trust | 0,07% | 4.136 SH | 8 de Agosto de 2026 | Diário |
| SMLF · iShares Trust | 0,07% | 57.970 SH | 8 de Agosto de 2026 | Diário |
| VXF · VANGUARD INDEX FUNDS | 0,06% | 1.106.455 SH | 8 de Agosto de 2026 | Diário |
| ESML · iShares Trust | 0,06% | 33.283 SH | 8 de Agosto de 2026 | Diário |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,06% | 108 NS | 31 de Maio de 2026 | N-PORT |
| WSML · iShares Trust | 0,04% | 5.486 SH | 8 de Agosto de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 13.170 SH | 8 de Agosto de 2026 | Diário |
| IWO · iShares Trust | 0,04% | 109.974 SH | 8 de Agosto de 2026 | Diário |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 1.736 SH | 8 de Agosto de 2026 | Diário |
| XT · iShares Trust | 0,03% | 21.837 SH | 8 de Agosto de 2026 | Diário |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,03% | 3.509 NS | 31 de Maio de 2026 | N-PORT |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 7.774 SH | 8 de Agosto de 2026 | Diário |
| ESGV · VANGUARD WORLD FUND | 0,01% | 20.627 SH | 8 de Agosto de 2026 | Diário |
| IYY · iShares Trust | 0,01% | 4.231 SH | 8 de Agosto de 2026 | Diário |
| ITOT · iShares Trust | 0,01% | 128.511 SH | 8 de Agosto de 2026 | Diário |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,01% | 15.609 NS | 31 de Maio de 2026 | N-PORT |
| IWV · iShares Trust | 0,01% | 25.457 SH | 8 de Agosto de 2026 | Diário |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,00% | 289 NS | 31 de Maio de 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 75.392 SH | 8 de Agosto de 2026 | Diário |